Regionally specific changes in levels of cortical S100β in bipolar 1 disorder but not schizophrenia

References

• Lieberman J A, Koreen A R. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophrenia Bulletin 1993; 19: 371–429
   PubMed Web of Science ®Google Scholar
• Sobczak S, Honig A, van Duinen M A, Riedel W J. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disorders 2002; 4: 347–356
   PubMed Web of Science ®Google Scholar
• Azmitia E C. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Research Bulletin 2001; 56: 413–424
   PubMed Web of Science ®Google Scholar
• Wilson C C, Faber K M, Haring J H. Serotonin regulates synaptic connections in the dentate molecular layer of adult rats via 5-HT1a receptors: evidence for a glial mechanism. Brain Research 1998; 782: 235–239
   PubMed Web of Science ®Google Scholar
• Sherstnev V V, Storozheva Z I, Proshin A T, Makhmutov R Y, Puzyrev A V. S100B protein in pro- and antiapoptotic doses produces different effects on defensive behavior in adult rats. Bulletin of Experimental Biology and Medicine 2003; 136: 543–547
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Falkai P, Ponath G, et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Molecular Psychiatry 2004; 9: 897–899
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Missler U, Arolt V, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry 2001; 6: 445–449
   PubMed Web of Science ®Google Scholar
• Lara D R, Gama C S, Belmonte-de-Abreu P, et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. Journal of Psychiatric Research 2001; 35: 11–14
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004; 29: 1004–1011
   PubMed Web of Science ®Google Scholar
• Schroeter M L, Abdul-Khaliq H, Fruhauf S, et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophrenia Research 2003; 62: 231–236
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Lara D R, Elkis H, et al. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophrenia Research 2000; 43: 91–95
   PubMed Web of Science ®Google Scholar
• Liu J, Shi Y, Tang J, et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochemical and Biophysical Research Communications 2005; 328: 335–341
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Lara D R, Portela L V, et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2002; 12: 269–272
   PubMed Web of Science ®Google Scholar
• Schroeter M L, Abdul-Khaliq H, Diefenbacher A, Blasig I E. S100 B is increased in mood disorders may be reduced by antidepressive treatment Neuroreport 2002; 13: 1675–1678
   PubMed Web of Science ®Google Scholar
• Pekny M, Pekna M. Astrocyte intermediate filaments in CNS pathologies and regeneration. The Journal of Pathology 2004; 204: 428–437
   PubMed Web of Science ®Google Scholar
• Martin L J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiology of Disease 2000; 7: 613–622
   PubMed Web of Science ®Google Scholar
• O'Barr S, Schultz J, Rogers J. Expression of the protooncogene bcl-2 in Alzheimer's disease brain. Neurobiology of Aging 1996; 17: 131–136
   PubMedGoogle Scholar
• Quintana J, Wong T, Ortiz-Portillo E, et al. Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biological Psychiatry 2003; 53: 12–24
   PubMed Web of Science ®Google Scholar
• Strakowski S M, Adler C M, Holland S K, Mills N, DelBello M P. A preliminary FMRI study of sustained attention in euthymic, unmedicated bipolar disorder. Neuropsychopharmacology 2004; 29: 1734–1740
   PubMed Web of Science ®Google Scholar
• Hill C, Keks N, Roberts S, et al. Problem of diagnosis in postmortem brain studies of schizophrenia. American Journal of Psychiatry 1996; 153: 533–537
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Press, Washington, DC 1994
   Google Scholar
• Dean B, Pavey G, McLeod M, Opeskin K, Keks N, Copolov D. A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. Journal of Affective Disorders 2001; 66: 147–158
   PubMed Web of Science ®Google Scholar
• Kingsbury A E, Foster O J, Nisbet A P, et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Research. Molecular Brain Research 1995; 28: 311–318
   PubMedGoogle Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 4350–4354
   PubMed Web of Science ®Google Scholar
• Jarskog L F, Gilmore J H, Selinger E S, Lieberman J A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry 2000; 48: 641–650
   PubMed Web of Science ®Google Scholar
• Jarskog L F, Selinger E S, Lieberman J A, Gilmore J H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. American Journal of Psychiatry 2004; 161: 109–115
   PubMed Web of Science ®Google Scholar
• Catts V S, Catts S V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. Schizophrenia Research 2000; 41: 405–415
   PubMed Web of Science ®Google Scholar
• Fatemi S H, Laurence J A, Raghi-Niknam M, et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research 2004; 69: 317–323
   PubMed Web of Science ®Google Scholar
• Johnston-Wilson N L, Sims C D, Hofmann J P, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Molecular Psychiatry 2000; 5: 142–149
   PubMed Web of Science ®Google Scholar
• Perrone-Bizzozero N I, Sower A C, Bird E D, Benowitz L I, Ivins K J, Neve R L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 14182–14187
   PubMed Web of Science ®Google Scholar
• Karson C N, Casanova M F, Kleinman J E, Griffin W S. Choline acetyltransferase in schizophrenia. American Journal of Psychiatry 1993; 150: 454–459
   PubMed Web of Science ®Google Scholar
• Roberts G W, Colter N, Lofthouse R, Johnstone E C, Crow T J. Is there gliosis in schizophrenia? Investigation of the temporal lobe. Biological Psychiatry 1987; 22: 1459–1468
   PubMed Web of Science ®Google Scholar
• Kleindienst A, McGinn M J, Harvey H B, Colello R J, Hamm R J, Bullock M R. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. Journal of Neurotrauma 2005; 22: 645–655
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Schmidt A P, Avila T T, et al. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sciences 2004; 76: 805–811
   PubMed Web of Science ®Google Scholar
• Margis R, Zanatto V C, Tramontina F, et al. Changes in S100 β cerebrospinal fluid levels of rats subjected to predator stress. Brain Research 2004; 1028: 213–218
   PubMed Web of Science ®Google Scholar
• Ziegler D R, Oliveira D L, Pires C, et al. Ketogenic diet fed rats have low levels of S100B in cerebrospinal fluid. Neuroscience Research 2004; 50: 375–379
   PubMed Web of Science ®Google Scholar
• Unden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. Journal of Trauma 2005; 58: 59–61
   PubMedGoogle Scholar
• Wong C H, Rooney S J, Bonser R S. S-100β release in hypothermic circulatory arrest and coronary artery surgery. The Annals Thoracic Surgery 1999; 67: 1911–1914
   PubMed Web of Science ®Google Scholar